The prevalence of metabolic associated fatty liver disease (MAFLD)/non-alcoholic fatty liver disease (NAFLD)
Conditions
Interventions
Healthy Control Group:None
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for the control group: Healthy individuals capable of providing informed consent, without chronic liver disease. 2. Inclusion criteria for MASLD patients: Based on hepatic steatosis (confirmed by histology on liver biopsy, imaging, or blood biomarkers) and meeting at least one of the following three conditions: overweight/obesity, type 2 diabetes mellitus, or metabolic dysfunction. Metabolic dysfunction is defined as the presence of at least two of the following metabolic risk factors: (1) Waist circumference >=90 cm in Asian men / >=80 cm in Asian women; (2) Blood pressure >=130/85 mmHg or on specific drug therapy; (3) Blood triglycerides >=150 mg/dL (>=1.7 mmol/L) or on specific drug therapy; (4) HDL-cholesterol =2.5; (8) High-sensitivity CRP >2 mg/L.
Exclusion criteria
Exclusion criteria: 1.Pregnancy or history of chronic liver disease. 2.Inability to tolerate CT examination. 3.MR contraindications. 4.Poor image quality on CT or MR (e.g., severe motion artifacts precluding lesion assessment).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver proton density fat fraction (PDFF) value;Liver CT attenuation value; | — |
Countries
China
Contacts
Public ContactFuhua Yan
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed